GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RUA Life Sciences PLC (FRA:AOHA) » Definitions » Price-to-Owner-Earnings

RUA Life Sciences (FRA:AOHA) Price-to-Owner-Earnings : (As of Jun. 25, 2024)


View and export this data going back to . Start your Free Trial

What is RUA Life Sciences Price-to-Owner-Earnings?

As of today (2024-06-25), RUA Life Sciences's share price is €0.11. RUA Life Sciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for RUA Life Sciences's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of RUA Life Sciences was 23.03. The lowest was 9.16. And the median was 14.73.


FRA:AOHA's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 31.42
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-25), RUA Life Sciences's share price is €0.11. RUA Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was €-0.10. Therefore, RUA Life Sciences's PE Ratio for today is At Loss.

As of today (2024-06-25), RUA Life Sciences's share price is €0.11. RUA Life Sciences's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.10. Therefore, RUA Life Sciences's PE Ratio without NRI for today is At Loss.

During the past 13 years, RUA Life Sciences's highest PE Ratio without NRI was 110.12. The lowest was 0.00. And the median was 99.82.


RUA Life Sciences Price-to-Owner-Earnings Historical Data

The historical data trend for RUA Life Sciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RUA Life Sciences Price-to-Owner-Earnings Chart

RUA Life Sciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

RUA Life Sciences Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of RUA Life Sciences's Price-to-Owner-Earnings

For the Medical Devices subindustry, RUA Life Sciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RUA Life Sciences's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where RUA Life Sciences's Price-to-Owner-Earnings falls into.



RUA Life Sciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

RUA Life Sciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.11/-0.10
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RUA Life Sciences  (FRA:AOHA) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


RUA Life Sciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of RUA Life Sciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


RUA Life Sciences (FRA:AOHA) Business Description

Traded in Other Exchanges
Address
2 Drummond Crescent, Scotland, Irvine, Ayrshire, GBR, KA11 5AN
RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives its major revenue from the USA and has a presence in Europe and the Rest of the world.

RUA Life Sciences (FRA:AOHA) Headlines

No Headlines